Celltrion "COVID-19 Treatment Phase 2 Clinical Results Show Reduced Recovery Time and 54% Decrease in Severe Cases"
Celltrion announced on the 13th that the Phase 2 clinical trial results of the COVID-19 virus infection treatment (CT-P59) showed a 54% reduction in the incidence of severe cases requiring hospitalization among all patients, and a 68% reduction among moderate cases aged 50 and above. Additionally, no serious adverse reactions, deaths, or study discontinuations due to adverse reactions following administration of the investigational drug were reported. Celltrion further explained that overall, no safety concerns were observed in the CT-P59 treatment group, demonstrating its safety.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- "It Has Now Crossed Borders": No Vaccine or Treatment as Bundibugyo Ebola Variant Spreads [Reading Science]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
